Health Care · Ophthalmic Goods · Nasdaq · CIK 1710155 · FYE Jan 2 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $22.40Day +2.05%Mkt cap $1.8B1Y −8.3%Off 52W high −25.4%Vol (1Y) 51.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,197 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesNEVER-OBSERVED · 38.2% growth |
| Short interest20.8% of sh out |
| Days to cover8.9d |
| 13F net flow (QoQ)+2.41% |
| Top-10 13F concentration48.1% |
| Next report (est.)2026-08-12 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$2.02B |
| Earnings (TTM)$46.6M |
| ROE3.5% |
| Net margin1.5% |
| ROIC3.9% |
| Debt / equity0.27× |
| YTD−13.2% |
| 1Y−8.3% |
| 3Y+3.6% |
| 5Y−58.5% |
| Since incept. (ann.)−2.4% |
Total return through 2026-07-30 · series begins 2017-10-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)51.9% |
| Ann. volatility (3Y)50.9% |
| Sharpe (1Y)0.08 |
| Sharpe (3Y)0.28 |
| Max drawdown (1Y)−47.6% |
| Max drawdown (3Y)−59.3% |
| Beta (3Y vs SPY)1.36 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 11.5M | $299M | — | +0.1% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.7M | $149M | — | new |
| WELLINGTON MANAGEMENT GROUP LLP | 5.5M | $142M | — | −5.0% |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 4.2M | $109M | — | −6.3% |
| Driehaus Capital Management LLC | 3.5M | $90M | — | −3.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4M | $89M | — | new |
| AMERICAN CENTURY COMPANIES INC | 3.2M | $84M | — | −9.9% |
| STATE STREET CORP | 3.2M | $82M | — | +0.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (95,318,737) exceed the cover-page shares-outstanding count for this quarter (79,437,185, as of 2026-02-20) by more than securities-lending double counting can explain (FINRA short interest 10,290,704 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-04-04 | 2026-05-13 | $0.38 | +111.1% | $543.9M | +6.6% |
| 2026-01-03 | 2026-03-04 | — | — | $503.4M | +15.1% |
| 2025-09-27 | 2025-11-05 | $0.04 | — | $487.3M | +7.9% |
| 2025-06-28 | 2025-08-06 | $0.11 | — | $486.4M | +7.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Product Sales 40% · Eyeglasses And Sunglasses 32% · Services And Plans 10% · Contact Lenses 8% · Exam 6%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Total debt / EBITDA1.58× |
| EPS growth 3Y−10.7% |
| Sales growth 3Y6.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
